In Global First, CARsgen’s Solid-Tumor CAR-T Therapy Nears China Approval

▤ Summary

CARsgen Therapeutics is nearing final China approval for satri-cel, a CAR-T therapy for advanced Claudin18.2-positive gastric and gastroesophageal junction cancers. If approved, it would become the world’s first marketed CAR-T treatment for solid tumors. Shanghai regulators are actively supporting the review, GMP inspection, and registration process to speed the launch. The milestone could broaden the CAR-T market and encourage wider clinical and commercial interest in cell therapy. The article also notes related CAR-T regulatory progress at another Chinese biotech company and highlights the sector’s growth outlook.

▦ Linked Companies